Clinical trials: Kerato Conjunctivitis Sicca
Ocular Inflammation, Keratoconjunctivitis
Tolerability Comparison of Flarex to Lotemax SM
This study compared the ocular tolerability of fluorometholone acetate ophthalmic suspension 0.1% (FLAREX) to loteprednol etabonate ophthalmic gel 0.38% (Lotemax SM) in adult subjects.
- Conditions
- Ocular Inflammation, Keratoconjunctivitis, Dry Eye Disease (DED), Post-operative Complications
- Trial name
- NCT07588074
- Testing
- Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38%
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Harrow Inc
Keratoconjunctivitis Sicca
A 1-Year Study in Multiple Clinics Testing Rebamipide Eye Drops for Dry Eye Compared With a Placebo
The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).
- Trial name
- NCT00201981
- Testing
- Rebamipide 1%, Rebamipide 2%
- Where
- 63 sites in United States
- Volunteers
- 755 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
A six-month clinical research trial to evaluate the effectiveness of an investigational medication for the treatment of dry eye syndrome in patients that have been diagnosed with moderate to severe dry eye syndrome, an autoimmune…
- Conditions
- Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid
- Trial name
- NCT00025818
- Testing
- Ophthalmic Emulsion
- Where
- 17 sites in United States
- Volunteers
- 290 people
- Sponsor
- Allergan
Dry Eye
Artificial Tears Study in Mild to Moderate Dry Eye Patients
The mean change in the subjective comfort score from baseline of the test group is at least 2.0 units less than that of the control group.
- Trial name
- NCT00607776
- Testing
- (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400, Systane
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Abbott Medical Optics
Keratoconjunctivitis Sicca
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
The purpose of this study is to determine whether 0.2% and 0.5% R348 Ophthalmic Solutions are safe and effective in the treatment of Patients with Keratoconjunctivitis Sicca.
- Trial name
- DROPS (NCT01900249)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 20 sites in United States
- Volunteers
- 204 people
- Sponsor
- Rigel Pharmaceuticals
Keratoconjunctivitis Sicca
A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of R348 eye drops in patients with dry eye disease.
- Trial name
- NCT01733992
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R348 Ophthalmic Solution, 1.0%
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Rigel Pharmaceuticals
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study
To evaluate the safety and efficacy of 1% Pro-ocular topical gel administered twice daily for 12 weeks in treatment of Dry Eye Disease
- Trial name
- NCT04884217
- Testing
- Pro-ocular™ Topical Gel
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- PharmaDax Inc.
Myopia
A Prospective Study of Two Daily Disposable Contact Lenses
The purpose of this study was to evaluate the performance of a novel silicone hydrogel contact lens, DAILIES TOTAL1® (DT1) compared to the standard hydrogel material in 1-DAY ACUVUE® MOIST® (1DAVM) contact lens in contact lens…
- Trial name
- NCT01636986
- Testing
- Delefilcon A contact lenses, Etafilcon A contact lenses
- Volunteers
- 62 people
- Sponsor
- Alcon Research
Keratoconjunctivitis Sicca, Dry Eye
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.
- Trial name
- NCT03925727
- Testing
- Tavilermide ophthalmic solution
- Where
- 22 sites in United States
- Volunteers
- 623 people
- Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
Dry Eye
Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye
The purpose of this study is to assess the safety and efficacy of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis) using the EyeGate® II Iontophoresis system in patients with dry eye.
- Trial name
- NCT01129856
- Testing
- Dexamethasone phosphate ophthalmic solution, Sodium citrate buffer solution
- Where
- 5 sites in United States
- Volunteers
- 198 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Dry Eye
A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes
The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- VELOS-1 (NCT03334539)
- Testing
- HL036 ophthalmic solution
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Keratoconjunctivitis Sicca
A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome
This study will evaluate the efficacy of Retaine™ ophthalmic emulsion in treating the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02139033
- Testing
- Retaine™
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Ocusoft, Inc.
Dry Eye Disease, Dry Eye
PMCF Study to Evaluate Performance and Safety of "CLHA-based Eyedrops" Used to Improve Lacrimal Abnormalities
Tear dysfunction, also known as Dry Eye Disease (DED) is frequently encountered in the clinical practice. It is a multifactorial disease of the ocular surface characterized by insufficient tear production, loss of homeostasis of…
- Conditions
- Dry Eye Disease, Dry Eye, Kerato Conjunctivitis Sicca
- Trial name
- NCT05823961
- Testing
- Cross-linked hyaluronic acid eye drops
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Dry Eye Disease
Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S Lipid Balance, a new eye drops, emulsion developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to…
- Trial name
- NCT06323395
- Testing
- Vizol S LIPID BALANCE eye drops, ophthalmic saline eye drops
- Where
- 2 sites in Serbia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Jadran Galenski laboratorij d.d.
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 2 (NCT02819284)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 62 sites in United States
- Volunteers
- 909 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Disease
Safety Study of Tivanisiran to Treat Dry Eye
This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).
- Trial name
- FYDES (NCT05310422)
- Testing
- Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
- Where
- 25 sites in United States
- Volunteers
- 301 people
- Sponsor
- Sylentis, S.A.
Dry Eye Disease
Evaluation of the Safety and Tolerability of Ocular Lubricants
The purpose of this study is to evaluate the safety and tolerability of three new artificial tear formulations in subjects with moderate dry eye disease.
- Trial name
- NCT06571656
- Testing
- FID123359 test formulation, FID123360 test formulation, FID123361 test formulation
- Where
- 5 sites in Australia
- Volunteers
- 73 people
- Sponsor
- Alcon Research
Dry Eye
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
The objective of this study was to compare the safety and efficacy of 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- VELOS-2 (NCT03846453)
- Testing
- HL036 Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 637 people
- Sponsor
- HanAll BioPharma Co., Ltd.